Finite‐Duration Venetoclax/Azacitidine Followed by Umbilical Cord Blood Infusion Improves Outcomes in Frail Elderly Patients With Untreated Acute Myeloid Leukemia—A Pilot Study
Open Access
- 19 May 2026
- journal article
- research article
- Published by Wiley in Cancer Medicine
- Vol. 15 (5) , e71943
Abstract
Background: Continuous venetoclax‐azacitidine (VA) therapy is currently the major intervention for elderly or unfit acute myeloid leukemia (AML) patients. However, moderate chemotherapy with finite‐duration VA could achieve comparable or superior efficacy to infinite‐duration VA. Additionally, umbilical cord blood (UCB) transfusion improves clinical safety for elderly patients. Therefore, this single‐center study presents an improved approach: A finite‐duration VA and decitabine priming with intermediate‐dose cytarabine followed by UCB infusion. Methods: We included elderly AML patients who underwent the treatment between March 2021 and May 2024. Induction and maintenance regimens were VA. Our consolidation therapy involved intravenous decitabine (20 mg/m 2 d1–3), intermediate‐dose cytarabine (1.0 g/m 2 q12h d4–5), with subsequent UCB infusion (1.5% ± 25% × 10 7 /kg) d7. Our endpoints included duration of response (DOR), overall survival (OS), and safety. Results: We analyzed 16 patients with a median follow‐up of 53.6 months (95% CI: 36.2–71.0 months), and 7 out of 16 participants were at adverse risk. The median VA cycle number prior to disease relapse was 5 (IQR: 4–6). The median DOR was 17.4 months (95% CI: 7.3–27.5 months), with a 1‐year DOR rate of 68.8% and a 2‐year DOR rate of 35.2%. The median OS was 24.9 months (95% CI: 9.8–40.1 months), with a 1‐ and 2‐year OS rate of 100% and 55.6%. Specifically, among the 8 patients with IDH1/2 mutations, 4 experienced sustained remission, with 1‐year OS of 100%. Hematological and non‐hematological toxicities remained manageable during the consolidation phase. Conclusions: We demonstrated prolonged survival, particularly in patients with IDH mutations, using the modified intervention. This approach holds significant value for elderly patients with untreated AML who are unfit for standard treatments.Keywords
This publication has 32 references indexed in Scilit:
- Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemiaOncotarget, 2015
- Low Dose Decitabine Treatment Induces CD80 Expression in Cancer Cells and Stimulates Tumor Specific Cytotoxic T Lymphocyte ResponsesPLOS ONE, 2013
- Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision makingLeukemia, 2013
- Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AMLBlood, 2011
- Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donorsBone Marrow Transplantation, 2011
- The effect of decitabine on megakaryocyte maturation and platelet releaseThrombosis and Haemostasis, 2011
- Effect of Cytarabine and Decitabine in Combination in Human Leukemic Cell LinesClinical Cancer Research, 2007
- Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia: a comparison studyThe Lancet, 2007
- Standardized, unrelated donor cord blood transplantation in adults with hematologic malignanciesBlood, 2001
- Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemiaBlood, 2001